$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Advertisement Sinscents Bad Intentions. Great Candles.

Latest from other desks

tml.THE MODERN
LEAP
Health / Medical Research

Stem Cell Infusion Cut Fractures in Ten-Woman Trial

A phase 1 trial in Cell gave ten women with advanced osteoporosis, ages 50 to 75, a single infusion of their own bone-marrow stem cells edited to home to bone. Fragility fractures fell from an average of eight a year to 0.5 a year over two years, with no serious adverse events and no control group.

Human bone-marrow-derived mesenchymal stem cells under a microscope (archive). Photo: Chinmaya Mahapatra / CC BY-SA 3.0, via Wikimedia Commons.
Summary

A 94 percent drop in fractures would change osteoporosis care if it holds. Ten patients, no placebo arm and no cell tracking mean the result is a beginning, not a verdict.

Tap a passage. React to the part that matters.

The trial's manifest fits in one breath. It's a first-in-human, phase 1, open-label study with a single arm and a single center, run at the University of Murcia in Spain and registered as NCT02566655. Ten women with advanced osteoporosis, ages 50 to 75, each received one intravenous infusion of mesenchymal stem cells taken from her own bone marrow. The study's stated job was safety and feasibility, and on that measure it passed: no serious adverse events occurred.

The cells carried an edit that ordinary stem cell infusions don't. Mesenchymal stem cells can rebuild bone, but infused cells usually can't find it. The Murcia team coated each patient's cells with a sugar, in a process called exofucosylation, that gives the cells a surface marker for docking in bone marrow blood vessels. The idea is a return address: the cells circulate, latch where bone is made, and get to work there.

The fracture numbers are the reason the paper drew attention. In the two years before treatment, the women averaged eight fragility fractures a year as a group rate. In the two years after the infusion, that rate fell to 0.5 a year, a drop of about 94 percent. Bone mineral density rose, bone tissue area rose, and markers of bone formation stayed elevated for about six months. Across the full follow-up, which ran more than three additional years per patient, fractures fell to 0.11 per patient-year.

Now the limits, which are structural rather than minor. Ten patients is a safety cohort, not an efficacy trial. There was no control group, so there's no comparison against women who received nothing, a placebo, or standard care alone. Most participants were also taking conventional osteoporosis drugs before and during the trial, which makes the cell therapy's own contribution hard to isolate. The researchers didn't track the infused cells afterward, so they can't show how many reached bone or how long they stayed.

One more disclosure belongs in the open. Co-author Robert Sackstein, a regenerative medicine specialist at the Miami Veterans Affairs Medical Center, holds intellectual property rights in the cell-engineering technology the trial used. That doesn't invalidate the data. It does mean the follow-up trial matters more, not less, and the Murcia group is preparing one: a larger study that randomizes patients to their own engineered cells, a healthy donor's engineered cells, or no cell treatment at all.

The condition isn't rare, which is why a ten-person result travels this far. Osteoporosis affects roughly 200 million women worldwide, and its fractures drive hospitalizations, lost independence and deaths in older patients every year. A one-time infusion that durably rebuilt bone would be a different kind of treatment from the daily and monthly drugs now on offer. This trial shows the approach is safe enough to test properly. The randomized trial is the test.

The patients' histories show what advanced disease looks like before any treatment enters the picture. The women had broken bones in their spines, hips and arms, often after little more than a stumble, at a rate of a fracture every year or two each. The Spanish team, led by bone-marrow transplant specialist José Moraleda, began the trial in 2015, a decade before the results appeared in Cell on October 29, 2026. That timeline is part of the finding's weight: the follow-up isn't a snapshot, it's years of fracture counts per patient.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.